@article{uranbaigali_davaalkham_otgonbayar_2019, 
  title={THE SERUM M2BPGI LEVEL CAN BE PRACTICAL TEST TO DIAGNOSE LIVER FIBROSIS AMONGOVERWEIGHT AND OBESE PATIENTS IN MONGOLIA}, 
  volume={Выпуск 4 2019}, 
  DOI={10.34673/ismu.2019.96.18.007}, 
  abstractNote={Aim: To diagnose liver fibrosis among overweight and obese population of 40-65 years in Mongolia by serum M2BPGi glyco-biomarker level. Methods. We enrolled 3315 people aged 40-65 years old who live in urban and rural areas. Questionnaires were obtained from participants, and anthropometric measurements, ultrasound, and laboratory tests were done. Serum M2BPGi level was directly measured with the chemilumines centenzyme immune method using an automatic immunoanalyzer. Statistical analysis was performed on SPSS ver. 20.0; SPSS Inc., Chicago, IL software. We used Pearson chi squaretest to estimate difference between parameters with percentage, and T test was used to estimate median difference. Ap value less than 0.05considered statistically significant. Results. 3315 people participated in this study. 1955 people were recruited from Ulaanbaatar (59.0%) 1360 people were from rural areas, and 1141 (34.4%) were male and 2174 were female (65.6%). 1326 (40%) of the surveyed were overweight and 1038 (31.3%) were obese. Elevation of serum M2BPGI glyco-biomarker was significantly different from body weight, age group and sex (p<0.0001). Conclusion. From total participants, 40% were overweight and 31.3% were obese. The liver fibrosis was found in 51.2% of obese and overweight patient.}, 
  publisher={ФГБОУ ВО ИГМУ МИНЗДРАВА РОССИИ}, 
  author={Uranbaigali, E. and Davaalkham, D. and Otgonbayar, R.}, 
  year={2019}
  }